Ascendis Pharma logo

Ascendis Pharma

ASND | NASDAQ
Chart Builder DCF Calculator
$271.73
-$3.66 (-1.33%)
At close: Nov 16, 2026, 4:00 PM ET
$260.02
-$11.71 (-4.31%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.33%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
78.9
Fundamentals Excellent
Market Sentiment Bullish
Moat Narrow
Sector Rank #27/1021 (Top 3%)

Key Statistics

Market Data

Market Cap $17.82B
1D Range
270.35 277.68
52W Range
196.63 277.68

Valuation (TTM)

PE 17.30
PB 10.31
EV/EBITDA 58.51

Valuation (NTM)

Forward PE 16.67
Forward PEG -0.03
Price Target $327.50
Loading financial charts...

Profile

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering...

Sector Healthcare
Industry Biotechnology
Employees 1,189
IPO Date Jan 28, 2015
Fiscal Year January - December

Latest News

Ascendis Pharma A/S Q3 Earnings Call Highlights

4 days ago · marketbeat.com

Ascendis Pharma A/S Q3 Earnings Call Highlights
Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript

4 days ago · seekingalpha.com

Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference

6 days ago · globenewswire.com

Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union

11 days ago · globenewswire.com

Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

11 days ago · globenewswire.com

Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

22 days ago · globenewswire.com

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

1 month ago · globenewswire.com

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

1 month ago · zacks.com

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

1 month ago · globenewswire.com

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Ascendis Pharma: Back To Full Independence

2 months ago · seekingalpha.com

Ascendis Pharma: Back To Full Independence

Earnings

Latest Earnings
Nov 12, 2026
EPS
$1.24
Beat +38.70%
REV
$418.76M
Beat +2.29%
Next Earnings
Feb 10, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
15
Consensus
Buy
Price Target
$326.00
Upside
+19.97%
Buy (15)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.